- About About
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
Policy Recommendations Utah
2020-21 Improvements and Recommendations
Regulators made a public announcement clarifying rules regarding telehealth recommendations, saying that while state law requires that a doctor give the recommendation in-person, renewals and subsequent visits may be conducted over the phone. New rules to allow out of state patients to apply for temporary cards were also issued. Additionally, patients will no longer have to purchase flower in 1-gram pods thanks to changes made by state regulators.
Utah banned Delta-8 THC products in 2019, however medical cannabis retailers in the state seem to be violating this law by stocking the products and even pushing them on patients over other cannabis products. Delta-8 tends to be synthetically derived as the cannabis plant naturally produces very little. The chemicals used in the synthesis may be harmful and there are no regulations requiring safety contaminant tests for these substances. Additionally, there are no studies indicating the safety of delta-8 that is synthetically derived and at quantities seen in these products. Utah regulators should move quickly to crack down hard on producers making and retailers selling delta-8 THC products.
In 2022, ASA recommends that Utah regulators continue extending more forms of access to patients by removing the requirement for concentrates to be separately recommended when other forms of cannabis don’t sufficiently treat the patient’s condition. The state should also consider allowing for patients and caregivers to grow cannabis at home to lower the impact of supply issues and cost on patients. Additionally, retailers should be allowed to offer patients curbside pickup so they can avoid potential contact with others as the pandemic continues.